NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company

Lund, Sweden, August 24, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm:
NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its
Chief Operating Officer, Jan Nilsson leaves the company.
The company is entering into a very important period and is expecting exciting
developments during the fall. Over the past several months, the business
strategy and organization have been re-oriented to optimize the way forward. As
one consequence the position of COO is no longer required.

“I have been involved in NeuroVive in different roles since 2010 and it has been
fantastic to be part of the development of the company to the position it holds
today. The company has a very interesting project portfolio and a strong
organization. The transition to our new CEO is now concluded which makes the
timing right for me to seek new challenges. I will of course follow the
company’s continued development with greatest interest”, says Jan Nilsson.

“Jan Nilsson has with great dedication, in combination with his vast knowledge
and experience, played a key role in NeuroVive, not only as COO but also as a
Director and for a period as interim CEO. Jan has been instrumental in managing
the challenges faced by NeuroVive in recent years. On behalf of the entire
company and its shareholders, I express our respect and appreciation for Jan and
wish him all the best in his new endeavors”, says Greg Batcheller, Chairman of
NeuroVive.

About NeuroVive

NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a
company committed to the discovery and development of highly targeted candidates
that preserve mitochondrial integrity and function in areas of significant
therapeutic need. NeuroVive's business approach is driven by value-adding
partnerships with mitochondrial research institutions and commercial partners
across the globe.

NeuroVive's portfolio consists of two clinical projects, one in acute kidney
injury (CicloMulsion®) and one in traumatic brain injury (NeuroSTAT®). The
candidate drug NeuroSTAT has orphan drug designation in Europe and in the US for
treatment of moderate to severe traumatic brain injury and is currently being
evaluated in the CHIC study. CicloMulsion is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. Furthermore, the
R&D portfolio consists of two late stage discovery programs and one compound in
preclinical development.

NeuroVive is listed on Nasdaq Stockholm, Sweden, Small Cap, under the ticker
symbol NVP. The share is also traded on the OTC Markets Group Inc market in the
US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTCQX Best Market.

For investor relations and media questions, please contact:
Cecilia Hofvander, NeuroVive, Tel: +46 (0)46 275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of the contact
person set out above, at 08:30 a.m. CEST on August 24, 2016.